BNBX — Applied DNA Sciences, Inc.
NASDAQ · Financial Services · Asset Management
$0.15
+$0.00 (+1.67%)
Applied DNA Sciences, Inc. (BNBX) is a asset management company listed on NASDAQ. It is led by Clay D. Shorrock Esq., J.D., based in 50 Health Sciences Drive, Stony Brook, NY, United States, 11790, with about 26 employees. BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. BNB Plus Corp. was formerly known as Applied DNA Sciences, Inc. and changed its name to BNB Plus Corp. in November 2025. The company was founded in 1983 and is based in Stony Brook, New York.
Net income was -$4.0M. BNBX currently screens at market cap $3.3M and trailing P/E 0.0.
Use this BNBX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BNBX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BNBX SEC filings page. Lician reads the product cache first so this HTML stays unique to Applied DNA Sciences, Inc. even when a live quote feed is slow.
About Applied DNA Sciences, Inc.
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. BNB Plus Corp. was formerly known as Applied DNA Sciences, Inc. and changed its name to BNB Plus Corp. in November 2025. The company was founded in 1983 and is based in Stony Brook, New York.
BNBX Key Statistics
Market Cap
$3.31M
Volume
15,527
Previous Close
$0.14
Day Range
$0.13 – $0.14
P/E Ratio
0.00
P/B Ratio
0.26
EPS
-$1.82
Revenue
$0.00
Net Income
-$7.09M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
26
BNBX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.09M | -$10.02M | -$8.27M | -$14.28M |
| EPS (Diluted) | -$1.82 | -$15.21 | -$0.93 | -$2.07 |
Total Assets
$12.79M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$6.43M
Operating Cash Flow
-$13.71M
Free Cash Flow
$0.00
Applied DNA Sciences, Inc. Company Information
- President & CEO
- Clay D. Shorrock Esq., J.D.
- Headquarters
- 50 Health Sciences Drive, Stony Brook, NY, United States, 11790
- Website
- www.bnbx.io
- Phone
- 631 240 8800
- IPO / Founded
- 2003-07-15
- Sector
- Financial Services
- Industry
- Asset Management